Filed Pursuant to Rule 424(b)(2)
Registration No. 333-279084-01
333-279084
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED JUNE 4, 2024
Prospectus Supplement to Prospectus dated May 2, 2024
Becton Dickinson Euro Finance S.à r.l.
€ % Notes due 20
Fully and Unconditionally Guaranteed by
Becton, Dickinson and Company
Becton Dickinson Euro Finance S.à r.l. (the “Issuer”) is offering € aggregate principal amount of % Notes due 20 (the “notes”). Interest on the notes will be payable in cash annually in arrears on of each year, beginning on , 2025. The notes will mature on , 20 .
The Issuer may, at its option, redeem the notes, in whole or in part, at any time and from time to time, at the applicable redemption prices described in this prospectus supplement. See “Description of Notes—Optional Redemption.” In addition, the Issuer may redeem the notes in whole, but not in part, at any time in the event of certain changes in the laws of a relevant Taxing Jurisdiction (as defined herein). See “Description of Notes—Redemption for Tax Reasons.” If a change of control triggering event occurs as described in this prospectus supplement under the heading “Description of Notes—Offer to Repurchase Upon Change of Control Triggering Event,” unless the Issuer has exercised its right to redeem such notes as described under “Description of Notes—Optional Redemption,” “Description of Notes—Special Mandatory Redemption” or “Description of Notes—Redemption for Tax Reasons,” the Issuer will be required to offer to purchase the notes from the holders.
Concurrently with this offering, Becton, Dickinson and Company (“BD”) is offering € aggregate principal amount of its % Notes due 20 (the “concurrent offering”). The closings of this offering and the concurrent offering are not conditioned on each other. The concurrent offering is being made by means of a separate prospectus supplement and not by means of this prospectus supplement. This prospectus supplement is not an offer to sell or a solicitation of an offer to buy any securities being offered in the concurrent offering. BD may, in the near term, also consider pursuing additional capital markets transactions, including potential offerings of U.S. dollar-denominated senior notes. See “Use of Proceeds.”
The Issuer and BD expect to use the net proceeds from this offering, together with proceeds from the concurrent offering, any additional offerings, borrowings under BD’s commercial paper program and cash on hand, (i) to fund the cash consideration payable by BD for the acquisition (the “Acquisition”) of the Critical Care business (the “Business”) of Edwards Lifesciences Corporation (“Seller Parent”) and its subsidiaries by BD and/or certain of its subsidiaries, (ii) to pay fees and expenses in respect of the foregoing, and (iii) for general corporate purposes. This offering is not conditioned upon the consummation of the Acquisition, which, if completed, will occur subsequent to the closing of this offering, and there can be no assurances that the Acquisition will be consummated on the terms described herein, or at all. See “Summary—Recent Developments—The Acquisition” and “Use of Proceeds.”
If (i) the Acquisition is not consummated on or before the later of (x) June 3, 2025; and (y) the date that is five business days after any later date to which Seller Parent and BD may agree to extend the “Outside Date” in the Acquisition Agreement (as defined below) (such later date, the “Special Mandatory Redemption End Date”) or (ii) BD notifies the trustee under the indenture that it will not pursue the consummation of the Acquisition, then the Issuer will be required to redeem the notes (the “Special Mandatory Redemption”) at a special mandatory redemption price equal to 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date (as defined herein) (subject to the right of holders of the notes of record on the relevant record date to receive interest due on an interest payment date falling prior to the Special Mandatory Redemption Date). The proceeds from this offering will not be deposited into an escrow account pending completion of the Acquisition or any Special Mandatory Redemption, nor will the Issuer be required to grant any security interest or other lien on those proceeds to secure any redemption of the notes. See “Description of Notes—Special Mandatory Redemption.”
The notes will be the Issuer’s direct, senior unsecured obligations and will be pari passu in right of payment with all of the Issuer’s other senior unsecured indebtedness from time to time outstanding. The notes will be fully and unconditionally guaranteed (the “guarantees”) on a senior unsecured basis by BD, the indirect parent company of the Issuer. BD’s guarantees will be senior unsecured obligations of BD and will be pari passu in right of payment with all of BD’s other senior unsecured indebtedness and guarantees from time to time outstanding. The notes will be issued in minimum denominations of €100,000 and in integral multiples of €1,000 in excess thereof.
The notes constitute a new issue of securities for which there is no established trading market. This document constitutes the listing particulars (the “Listing Particulars”) in respect of the admission of the notes to the Official List and to trading on the Global Exchange Market (the “GEM”) of Euronext Dublin. Application has been made to the Irish Stock Exchange plc trading as Euronext Dublin (“Euronext Dublin”) for the approval of this document as the Listing Particulars. Application has been made to Euronext Dublin for the notes to be admitted to the Official List and to trade on the GEM of Euronext Dublin. The GEM is not a regulated market for the purposes of Directive 2014/65/EU (as amended, “MiFID II.”)
Investing in the notes involves risks that are described in the “Risk Factors” section of this prospectus supplement beginning on page S-
9 and in BD’s latest Annual Report on Form 10-K, which is incorporated by reference into this prospectus supplement (as such risk factors may be updated from time to time in BD’s public filings).
None of the Securities and Exchange Commission (the “SEC”), the Luxembourg Financial Sector Authority (the Commission de Surveillance du Secteur Financier) or any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense.
Note
|
|
|
% |
|
|
€ |
|
|
% |
|
|
€ |
|
|
% |
|
|
€ |
Total
|
|
|
|
|
|
€ |
|
|
|
|
|
€ |
|
|
|
|
|
€ |
(1)
|
Plus accrued interest from June , 2024, if settlement occurs after that date. |
We expect that delivery of the notes will be made to investors in book-entry form under the New Safekeeping Structure (the “NSS”) through Euroclear Bank SA/NV (“Euroclear”) and Clearstream Banking S.A. (“Clearstream”) (together, Euroclear and Clearstream are referred to herein as the “ICSDs”), on or about June , 2024. Upon issuance, the notes will be represented by global notes in registered form (the “Global Notes”), which are expected to be deposited with a common safekeeper (“Common Safekeeper”) for Euroclear and Clearstream and registered in the name of a nominee of the Common Safekeeper.
The notes are intended to be held in a manner which will allow Eurosystem eligibility. This simply means that the notes are intended upon issue to be deposited with one of the ICSDs as Common Safekeeper (and registered in the name of a nominee of one of the ICSDs acting as Common Safekeeper) and does not necessarily mean that the notes will be recognized as eligible collateral for Eurosystem monetary policy and intra-day credit operations by the Eurosystem either upon issue or at any or all times during their life. Such recognition will depend upon the European Central Bank being satisfied that Eurosystem eligibility criteria have been met.
Joint Book-Running Managers
Citigroup |
|
|
Barclays |
|
|
BNP PARIBAS |
|
|
J.P. Morgan |
|
|
Wells Fargo
Securities
|
The date of this prospectus supplement is June , 2024.